This study is looking at whether giving 17-hydroxyprogesterone caproate (17 OHPC) can improve outcomes for mothers and babies when preeclampsia is diagnosed early in pregnancy (before 34 weeks). Preeclampsia is a serious pregnancy complication characterized by high blood pressure and signs of damage to another organ system, most often the liver and kidneys. You may be able to join if you are a woman between 18 and 45 years old, are pregnant with preeclampsia between 23 and 34 weeks gestation, and are a patient at UMMC. The study aims to see if this treatment leads to better health for both mother and baby. The current status of this study is unclear, and it plans to enroll 60 participants.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 60 women.

What's involved

If you join, you will receive 17 OHPC injections at admission and every 7 days. Blood samples will be taken at various times until after delivery, and your placenta will be collected after birth.

Compensation

Not stated in the trial record.

Follow-up

Information about the mother and newborn will be collected while in the hospital and until discharge.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.